medigraphic.com
ISSN 1561-3062 (Electronic)

2016, Number 1

<< Back Next >>

Revista Cubana de Obstetricia y Ginecología 2016; 42 (1)

Non neoplastic findings and epithelial cell abnormalities in cervical cytology

Moya-Salazar J, Rojas-Zumaran V, Torres-Martínez R, Rosas-Vargas L

Language: Spanish
References: 51
Page:
PDF size: 170.21 Kb.


ABSTRACT

Introduction: The Pap test aims at diagnosing precancerous or cancerous lesions of the cervix, hormonal evaluation, and bacterial flora.
Objectives: Determine the proportion of non-neoplastic findings, squamous and glandular epithelial abnormalities referred to the district of Hospital Nacional Docente Madre Niño "San Bartolome".
Methods: A prospective, analytical, correlational, cross-sectional research was designedfor all vaginal smear which were referred from five health networks and micro-networks. Cytological processing was carried out in accordance with applicable international requirements. Cytologic interpretation was performed according to Bethesda System.
Results: Out of 72,644 cervical smears evaluated by Bethesda quality system, the proportion of results with cervical uterine disorders (prevalence 6.5 % CI 95 %: 6.32 %, 6.68 %) were 4724 (6.5 %) samples, negative posevaluación was 35318 (51.7 %) samples, and nonneoplastic findings 32 602 (48.2 %) samples, (p ‹ 0.005). Posttest probability was 89.3 % (CI 95 %: 87.1 % to 91.1 %; likelihood ratio LR › 10) and a significant direct correlation was established between the findings/nLiM and ages of patients (rho= 0.477; p ‹ 0.005). Moreover, 46.53 % of NIM flora suggestive corresponds to bacterial vaginosis (BV), 22.5 % to reactive changes associated with inflammation and squamous metaplasia 21 % (MET). The most frequent association was MET, VB, and severe inflammation 5.5 % (1495 results).
Conclusions: The proportion of non-neoplastic findings was considerable; squamous and glandular epithelial abnormalities were above average standard.


REFERENCES

  1. Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Peru. Summary Report. [Citado 07 de octubre de 2015].

  2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC, Cancer Base No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013.

  3. Fernández de Casadevante V, Gil Cuesta J, Cantarero-Arévalo L. Determinants in the uptake of the human papillomavirus vaccine: a systematic review based on European studies. Front Oncol. 2015;5:141.

  4. Moya SJ, Pio DL. Prevalence of cervical-uterine abnormalities associated with poverty levels at “Hospital Nacional Docente Madre Niño San Bartolome” between 2011-2013. Rev Invest Universidad Norbert Wiener. 2014;3(1):89-99.

  5. Signan N. Socioeconomic status and cancer screening. In: Kogevinas M, Pearce N, Susser M, Boffetta P. Social inequalities and cancer. Lyon: International Agency for Research on Cancer; 1997. p. 369-76.

  6. Pereira-Scalabrino A, Almonte M, dos-Santos-Silva I. Country-level correlates of cervical cáncer mortality in Latin America and the Caribbean. Salud Publica Mex. 2013;55(1):5-15.

  7. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J ClinPathol. 2002;55:244-65.

  8. Zur Hansen H. Infections Causing Human Cancer. Weinheim: Wiley-VCH. 2006. p. 145-98.

  9. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1157-64.

  10. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J ClinVirol. 2005;32(S1):16-24.

  11. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2):278-85.

  12. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119-50.

  13. Silins I, Ryd W, Strand A, Wadell G, Törnberg S, Hansson BG, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer. 2005;116(1):110-5.

  14. Friedek D, Ekiel A, Chełmicki Z, Romanik M. [HPV, Chlamydia trachomatis and genital mycoplasmas infections in women with low-grade squamous intraepithelial lesions (LSIL)]. Ginekol Pol. 2004;75(6):457-63.

  15. Deluca GD, Basiletti J, Schelover E, Vásquez ND, Alonso JM, Marín HM, et al. Chlamydia trachomatis as a probable cofactor in human papillomavirus infection in aboriginal women from northeastern Argentina. Braz J Infect Dis. 2011;15(6):567-72.

  16. Zheng MY, Zhao HL, Di JP, Lin G, Lin Y, Lin X, et al. Association of human papillomavirus infection with other microbial pathogens in gynecology. Zhonghua Fu Chan KeZaZhi. 2010;45(6):424-8.

  17. Rodriguez-Cerdeira C, Sanchez-Blanco E, Alba A. Evaluation of Association between Vaginal Infections and High-Risk Human Papillomavirus Types in Female Sex Workers in Spain. Obstet Gynecol. 2012.

  18. Bhatla N, Puri K, Joseph E, Kriplani A, Iyer VK, Sreenivas V. Association of Chlamydia trachomatis infection with human papillomavirus (HPV) & cervical intraepithelial neoplasia -a pilot study. Indian J Med Res. 2013;137(3):533-9.

  19. Gaitán DH, Rubio RJ, Eslava SJ. Asociación de la citología cérvico-vaginal inflamatoria con la lesión intraepitelial cervical en pacientes de una Clínica de Salud Sexual y Reproductiva, en Bogotá, Colombia 1999-2003. Rev Salud Pública. 2004;6(3):253-69.

  20. Christian CD. Maternal deaths associated with an intrauterine device. AJOG 1974;119(4):441-4.

  21. Castellsagué X, Díaz M, Vaccarella S, de Sanjosé S, Muñoz N, Herrero R, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol. 2011;12(11):1023-31.

  22. Singh V, Parashari A, Satyanarayana L, Sodhani P, Gupta MM, Sehgal A. Biological behavior and etiology of inflammatory cervical smears. Diagn Cytopathol. 1999;20:199-202.

  23. Kaplan B, Orvieto R, Hirsch M, Rabinerson D, Braslavski D, Bar-Hava I, et al. The impact of intrauterine contraceptive devices on cytological findings from routine Pap smear testing. Eur J Contracept Reprod Health Care. 1998;3:75-7.

  24. Paler R, Simpson D, Kaye A, Gunn S, Felix J. The relationship of inflammation in the papanicolaou smear to Chlamydia trachomatis infection in a high-risk population. Contraception. 2000;61(3):231-4.

  25. Moya-Salazar J, Rojas-Zumaran V, Torres-Martínez R, Rosas-Vargas L. Calidad de los extendidos Cérvico-uterinos dentro de la coloración de Papanicolaou para el cribado de cáncer cervical en Lima, Perú. Rev Esp Patol. 2015; In press.

  26. Parkin DM, Whelan S, Ferlay J. Cancer incidence in five continents. Vol. I to VIII. Lyon: IARC scientific publication. 2002;I-VIII:78.

  27. Nayar R, Wilbur DC. The Bethesda System for Reporting Cervical Cytology. Definitions, Criteria and Explanatory Notes. 3th ed. Switzerland: Springer; 2015.

  28. Instituto Nacional de salud (INS). Manual de procedimientos para el diagnóstico en citología cérvico-uterina. Serie de normastécnicas. MINSAP. 2005;43.

  29. Brome BM, Mendoza RA, García AM, Restrepo CJ. Manual de Citología Cérvico-uterina. Secretaría Seccional de Salud y Protección Social de Antioquia. 2010.

  30. Solomon D, Nayar R. The Bethesda System for Reporting Cervical Cytology. New York: Spring Science; 2001.

  31. WHO. Global recommendations on physical activity for health. Geneva; 2010.

  32. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV Screening for Cervical Cancer in Rural India. N Engl J Med. 2009;360(14):1385-94.

  33. Palaoro LA, Rocher AE, de Torres R. The inflammatory genital reaction in the detection of alterations by human papilloma virus. Acta Bioquím Clín Latinoam. 2013;47(3).

  34. Mardh PA. The definition and epidemiology of bacterial vaginosis. Rev Fr Gynecol Obstet. 1993;88:195-7.

  35. Jorge AS, Vaz de Lima R, Elias ZT, Gobo SM, Hazarabedian AM, Saldanha JC, et al. Frequency of Trichomonavaginalis, Candida sp and Gardnerella vaginalis in cervical-vaginal smears in four different decades. Sao Paulo Med J. Rev Paul Med. 2001;119(6):200-5.

  36. Kenyon C, Colebunders R, Crucitti. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013;209(6):505-23.

  37. Friedrich EG Jr. Vaginitis. Am J Obstet Gynecol. 1985;152:247-51.

  38. Florino AS. Intrauterine contraceptive device-associated actinomycotic abscess and Actinomyces detection on cervical smear. Obstet Gynecol. 1996;87(1):142-9.

  39. Prozialeck WC, Fay MJ, Lamar PC, Pearson CA, Sigar I, Ramsey KH. Chlamydia trachomatis Disrupts N-Cadherin-Dependent Cell-CellJunctions and Sequesters -Catenin in Human Cervical Epithelial Cells. Infect Immun. 2002;70(5):2605-13.

  40. Silva LC, Miranda AE, Batalha RS, Sabino CC, Dib E, Costa CM, et al. Chlamydia trachomatis infection among HIV-infected women attending an AIDS clinic in the city of Manaus, Brazil. Braz J Infect Dis. 2012;16(4):335-8.

  41. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. 2007;4(12):e329.

  42. Yelverton CL, Bentley RC, Olenick S, Krigman HR, Johnston WW, Robboy SJ. Epithelial repair of the uterine cervix: Assessment of morphologic features and correlations with cytologic diagnosis. Int J GynecolPathol. 1996;15:338-44.

  43. Ng WK, Cheung LK, Li AS, Chow JC. Significance of atypical repair in liquid-based gynaecologic cytology: A follow-up study with molecular analysis for human papillomavirus. Cancer. 2003;99:141-8.

  44. Seckin N, Turhan N, Ozmen S, Ersan F, Avsar F Ustun H. Routine colposcopic evaluation of patients with persistent inflammatory cellular changes on Pap smear. Int J Gynaecol Obstet. 1997;59:25-9.

  45. Posada RA. Concordancia entre los hallazgoscitológicos de ASC-US enatrofia y metaplasia con la biopsiaen el laboratorio de Patología de ClínicaColsanitas S.A. durante los años 2009 a 2012. [Tesis]. Colombia: Universidad Nacional de Colombia, Facultad de Medicina, Departamento de Patología; 2015.

  46. Barr SooferS, Sidawy MK. Reactive cellular change: is there an increased risk for squamous intraepithelial lesions? Cancer. 1997;81:144-7.

  47. Malik SN, Wilkinson EJ, Drew PA, Hardt NS. Benign cellular changes in Pap smears. Causes and signifi cancer. Acta Cytol. 2001;45:5-8.

  48. Plummer G, Masterson JG. Herpes Simplex virus and cáncer of the cérvix. Am J Obstet Gynec. 1971;111:81.

  49. Mays RM, Zimet GD, Winston Y, Kee R, Dickes J, Su L. Human papillomavirus, genital warts, pap smears, and cervical cancer: knowledge and beliefs of adolescent and adult women. Health Care Women Int. 2000;21:361-74.

  50. Morera AF, Ramírez BM, Miranda GG. Estudio comparativo de dos métodos de tamizaje para el diagnóstico de las patologías cervicouterinas en mujeres de 15 a 35 años en la Clínica de Jicaral, Puntarenas. [Tesis] Costa Rica: Universidad Estatal a Distancia Vicerectoria Académica. Escuela de Ciencias Exactas y Naturales; 2005.

  51. Cervical Cancer Action. Progreso en la Prevención del Cáncer Cervicouterino: Informe de Cervical Cancer Action. [Internet]. CCA; 2001. Disponible en: www.cervicalcanceraction.org




2020     |     www.medigraphic.com